13F filer · CIK 1562230 ↗
Capital International Investors
You are looking at Q1 2022. See the latest, Q2 2026 →
Reported value
$438.61B
−7.3% on the quarter before
Positions
454
34 new · 40 sold out
Top 10
27.4%
of the value
Est. gain
−$28.28B
on stocks held all quarter
Est. return
−6.6%
on those stocks since Q4 2021
Positions as of Mar 31, 2022, from Capital International Investors's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 42% of the reported value, each sized by its share, colored by what the fund did with it since Q4 2021. Striped tiles are options.
Largest buys
Since Q4 2021, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Abbvie Inc~$3.06BAdded · 0.3% → 1.1%+18,882,699 shares
- Pfizer Inc~$1.93BAdded · 0.0% → 0.5%+37,310,556 shares
- Bristol-Myers Squibb Co~$1.67BNew · 0.0% → 0.4%+22,900,931 shares
- Morgan Stanley~$1.59BAdded · 0.1% → 0.4%+18,150,967 shares
- Constellation Energy Corp~$1.25BNew · 0.0% → 0.3%+22,154,364 shares
- Regeneron Pharmaceuticals~$990.3MAdded · 0.0% → 0.3%+1,417,899 shares
- Apollo Global Mgmt Inc~$974.2MNew · 0.0% → 0.2%+15,715,583 shares
- Zoetis Inc~$936.3MAdded · 0.0% → 0.2%+4,964,646 shares
- Archer Daniels Midland Co~$847.5MNew · 0.0% → 0.2%+9,389,631 shares
- Horizon Therapeutics Pub L~$744.5MNew · 0.0% → 0.2%+7,075,657 shares
Largest sells
Since Q4 2021, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Activision Blizzard Inc~$2.84BCut · 0.6% → 0.1%−35,461,749 shares
- Gilead Sciences Inc~$1.81BCut · 0.6% → 0.1%−30,413,697 shares
- Union Pac Corp~$1.68BCut · 0.3% → 0.0%−6,139,801 shares
- Exelon Corporation~$1.35BCut · 0.7% → 0.3%−28,372,276 shares
- Microsoft~$1.33BCut · 6.5% → 6.1%−4,303,134 shares
- Broadcom~$1.26BCut · 4.5% → 4.3%−1,996,797 shares
- Merck & Co Inc~$1.23BCut · 0.3% → 0.0%−15,017,143 shares
- Vale S A~$939.8MCut · 0.6% → 0.7%−47,013,157 shares
- Moody's Corporation~$809.7MCut · 0.4% → 0.2%−2,399,583 shares
- Pnc Finl Svcs Group Inc~$764.3MCut · 0.5% → 0.4%−4,143,529 shares
Holdings
As of Mar 31, 2022. Changes are in shares against Dec 31, 2021, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MicrosoftCOM · shares −4.7% · price −8.3% | 6.1% | $26.73B | −$2.43B | ||||||||
| BroadcomCOM · shares −6.3% · price −5.4% | 4.3% | $18.82B | −$1.07B | ||||||||
| AmazonCOM · shares +6.1% · price −2.2% | 2.9% | $12.83B | −$275.5M | ||||||||
| MetaCL A · shares +4.4% · price −33.9% | 2.7% | $12.02B | −$5.90B | ||||||||
| AlphabetCAP STK CL C · shares −4.9% · price −3.5% | 2.5% | $10.83B | −$388.8M | ||||||||
| Unitedhealth Group IncCOM · shares −3.5% · price +1.6% | 2.2% | $9.52B | +$147.9M | ||||||||
| Comcast Corp NewCL A · shares −6.2% · price −7.0% | 2.2% | $9.51B | −$711.7M | ||||||||
| Philip Morris Intl IncCOM · shares +2.1% · price −1.1% | 1.6% | $7.12B | −$78.2M | ||||||||
| NetflixCOM · shares −3.0% · price −37.8% | 1.6% | $6.92B | −$4.21B | ||||||||
| Abbott LabsCOM · shares −4.1% · price −15.9% | 1.4% | $5.95B | −$1.12B | ||||||||
| MastercardCL A · shares +9.7% · price −0.5% | 1.3% | $5.80B | −$28.7M | ||||||||
| Northrop Grumman CorpCOM · shares −1.4% · price +15.6% | 1.3% | $5.57B | +$750.0M | ||||||||
| ConocophillipsCOM · shares −10% · price +38.5% | 1.1% | $4.97B | +$1.38B | ||||||||
| Abbvie IncCOM · shares +163% · price +19.7% | 1.1% | $4.94B | +$310.2M | ||||||||
| IntelCOM · shares −6.8% · price −3.7% | 1.1% | $4.75B | −$184.9M | ||||||||
| Eog Res IncCOM · shares −10.0% · price +34.2% | 1.0% | $4.53B | +$1.15B | ||||||||
| Charter Communications Inc NCL A · shares −11% · price −16.3% | 1.0% | $4.47B | −$871.3M | ||||||||
| Jpmorgan Chase & CoCOM · shares −12% · price −13.9% | 1.0% | $4.44B | −$716.0M | ||||||||
| Chubb LimitedCOM · shares −3.6% · price +10.7% | 0.99% | $4.32B | +$416.6M | ||||||||
| AppleCOM · shares +5.8% · price −1.6% | 0.98% | $4.32B | −$68.2M | ||||||||
| Transdigm Group IncCOM · shares +0.07% · price +2.4% | 0.97% | $4.27B | +$100.5M | ||||||||
| AlphabetCAP STK CL A · shares −9.5% · price −4.0% | 0.97% | $4.27B | −$177.5M | ||||||||
| Raytheon Technologies CorpCOM · shares +12% · price +15.1% | 0.93% | $4.08B | +$478.3M | ||||||||
| Chevron Corp NewCOM · shares −6.9% · price +38.8% | 0.89% | $3.92B | +$1.10B | ||||||||
| Johnson & JohnsonCOM · shares −0.9% · price +3.6% | 0.81% | $3.55B | +$123.5M | ||||||||
| Total · 454 positions | 100% | $438.61B | −$28.28B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2021 to Q1 2022: 419 stocks held throughout, down $28.28B (−6.6%).
- Conocophillips+$1.38B+39%
- Eog Res Inc+$1.15B+34%
- Chevron Corp New+$1.10B+39%
- Vale S A+$935.4M+43%
- Northrop Grumman Corp+$750.0M+16%
- Broadcom−$1.07B−5%
- Abbott Labs−$1.12B−16%
- Microsoft−$2.43B−8%
- Netflix−$4.21B−38%
- Meta−$5.90B−34%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 12, 2026 | $483.61B+13% | SEC ↗ |
| Q1 2026 | May 13, 2026 | $426.52B−33% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $637.97B+3% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $619.40B+7% | SEC ↗ |
| Q2 2025 | Aug 13, 2025 | $580.56B+14% | SEC ↗ |
| Q1 2025 | May 12, 2025 | $508.52B−4% | SEC ↗ |
| Q4 2024 | Feb 13, 2025 | $532.30B+2% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $520.97B+7% | SEC ↗ |
| Q2 2024 | Aug 13, 2024 | $485.73B−2% | SEC ↗ |
| Q1 2024 | May 14, 2024 | $493.90B+11% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $446.09B+13% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $394.11B−5% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $414.45B+7% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $388.71B+4% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $372.54B+9% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $342.83B−7% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $367.64B−16% | SEC ↗ |
| Q1 2022 | May 19, 2022 (amended) | $438.61B−7% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $473.03B+8% | SEC ↗ |
| Q3 2021 | Nov 15, 2021 | $437.44B−0% | SEC ↗ |
| Q2 2021 | Aug 16, 2021 | $437.89B+11% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $395.24B+8% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $366.38B+13% | SEC ↗ |
| Q3 2020 | Nov 13, 2020 | $323.46B+6% | SEC ↗ |
| Q2 2020 | Aug 14, 2020 | $305.21B+25% | SEC ↗ |
| Q1 2020 | May 15, 2020 | $244.50B−17% | SEC ↗ |
| Q4 2019 | Feb 18, 2020 | $294.42B+12% | SEC ↗ |
| Q3 2019 | Nov 14, 2019 | $261.94B+5% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $250.64B+8% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $232.80B+16% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $200.60B−8% | SEC ↗ |
| Q3 2018 | Nov 14, 2018 | $218.36B+147% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 | $88.55B+2% | SEC ↗ |
| Q1 2018 | May 15, 2018 | $86.51B−2% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 | $88.52B+6% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 | $83.48B+11% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 | $74.88B+2% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $73.61B+6% | SEC ↗ |
| Q4 2016 | Feb 15, 2017 | $69.28B+0% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $68.95B+1% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 | $68.21B+5% | SEC ↗ |
| Q1 2016 | May 16, 2016 | $65.22B | SEC ↗ |